Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of D-Eflornithine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 known ✓ | P11926 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | BLM | P54132 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | ARG1 | P05089 | 3/20 | 0.62 |
| ▸ | ARG2 | P78540 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eflornithine SCHEMBL8581344 | 1.00 | ODC1 (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL26327 | 1.00 | ODC1 (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine, (S)- SCHEMBL60698 | 1.00 | ODC1 (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL6779168 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| D-Eflornithine SCHEMBL7208883 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL3244711 | 0.98 | ODC1 (0.96) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine, (S)- SCHEMBL6779172 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine SCHEMBL3022583 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT | |
| D-Eflornithine SCHEMBL3244719 | 0.98 | ODC1 (0.96) | ODC1LMNABLMKDM4EMAPT | |
| Eflornithine, (S)- SCHEMBL1322403 | 0.98 | BLM (1.00) | ODC1LMNABLMKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 980 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041256-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | ORBUS THERAPEUTICS INC (US) | 2025-02-06 | — | — | US | claimed |
| CN-112481337-B | High mannose glycoform content of regulatory ornithine metabolism to manipulate recombinant proteins | 美国安进公司 | 2024-06-25 | — | — | CN | claimed |
| US-20220142948-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-05-12 | — | — | US | claimed |
| EP-3942023-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | The Broad Institute, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| CN-112481337-A | Modulation of ornithine metabolism to manipulate high mannose glycoform content of recombinant proteins | 美国安进公司 | 2021-03-12 | — | — | CN | claimed |
| WO-2020191079-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC REGULATORS OF T CELL PATHOGENICITY | THE BROAD INSTITUTE, INC. (US) | 2020-09-24 | — | — | WO | claimed |
| EP-2440195-B1 | USE OF ALKYLGLYCEROLS FOR PREPARING DRUGS | UNIV RENNES (FR) | 2019-11-06 | — | — | EP | claimed |
| CN-110267649-A | Immunomodulatory compounds | 兰肯瑙医学研究所 | 2019-09-20 | — | — | CN | claimed |
| CN-105660637-B | Prevent the medicine and its application of Angelica sinensis morning a kind of sedge | 南京中医药大学 | 2018-04-24 | — | — | CN | claimed |
| CN-106718821-A | A kind of method for suppressing rice thermosensitive genie male sterile Fertility al-teration during the production of hybrid seeds | 南京农业大学 | 2017-05-31 | — | — | CN | claimed |
| EP-0543949-A1 | ENZYMIC ALTERATION OF HAIR GROWTH. | HANDELMAN JOSEPH H (US) | 1993-06-02 | — | — | EP | claimed |
| US-5132293-A | Enzyme inhibitors | SHANDER DOUGLAS (US) | 1992-07-21 | — | — | US | claimed |
| WO-1992003140-A1 | ENZYMIC ALTERATION OF HAIR GROWTH | HANDELMAN JOSEPH H (US) | 1992-03-05 | — | — | WO | claimed |
| CN-88100500-A | NOVEL POLYAMINE DERIVATIVES | — | 1988-09-07 | — | — | CN | claimed |
| EP-0277635-A2 | Novel polyamine derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-08-10 | — | — | EP | claimed |
| US-4760091-A | Applying fungicidally effective amount of an ornithine decarboxylase inhibitor | THE DOW CHEMICAL COMPANY (US) | 1988-07-26 | — | — | US | claimed |
| EP-0248217-A2 | Use of ornithine decarboxylase inhibitor for preparing a medicament for use in the treatment, in conjuction with LAK cells and interleukin-2, of tumors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-12-09 | — | — | EP | claimed |
| EP-0211354-A2 | Nucleosides and their use as antineoplastic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-02-25 | — | — | EP | claimed |
| EP-0162413-A2 | Polyamine for use as a medicine in the treatment of neoplasms | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-11-27 | — | — | EP | claimed |
| US-4499072-A | Process for treating diseases with ODC inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-02-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041256-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, SHMT1 | ODC1 19/4885LMNA 2211/4885BLM 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.